Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience (NASDAQ: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders treatments, has scheduled its Q1 2025 earnings conference call for May 8th, 2025, at 1:30 PM PT/4:30 PM ET. The company will release its financial results after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation through Skye's Investor Relations website. A replay and transcript will be available post-call on the same platform.
Skye Bioscience (NASDAQ: SKYE), un'azienda biotecnologica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi metabolici, ha programmato la sua conference call sui risultati del primo trimestre 2025 per il 8 maggio 2025, alle 13:30 PT/16:30 ET. La società comunicherà i risultati finanziari dopo la chiusura del mercato lo stesso giorno. Gli investitori potranno accedere alla diretta web, al comunicato sugli utili, alle tabelle finanziarie e alla presentazione tramite il sito web delle Relazioni con gli Investitori di Skye. Una registrazione e la trascrizione saranno disponibili dopo la chiamata sulla stessa piattaforma.
Skye Bioscience (NASDAQ: SKYE), una empresa biotecnológica en etapa clínica especializada en tratamientos para la obesidad y trastornos metabólicos, ha programado su conferencia telefónica de resultados del primer trimestre de 2025 para el 8 de mayo de 2025 a la 1:30 PM PT/4:30 PM ET. La compañía publicará sus resultados financieros después del cierre del mercado ese mismo día. Los inversores podrán acceder a la transmisión en vivo, el comunicado de resultados, las tablas financieras y la presentación a través del sitio web de Relaciones con Inversores de Skye. Una repetición y la transcripción estarán disponibles después de la llamada en la misma plataforma.
Skye Bioscience (NASDAQ: SKYE)는 비만 및 대사 질환 치료를 전문으로 하는 임상 단계 바이오테크 기업으로, 2025년 1분기 실적 컨퍼런스 콜을 2025년 5월 8일 오후 1시 30분 PT/오후 4시 30분 ET에 예정하고 있습니다. 회사는 같은 날 시장 마감 후 재무 결과를 발표할 예정입니다. 투자자들은 Skye의 투자자 관계 웹사이트를 통해 실시간 웹캐스트, 실적 발표, 재무 표 및 프레젠테이션에 접속할 수 있습니다. 콜 종료 후에는 동일 플랫폼에서 다시보기 및 녹취록도 제공됩니다.
Skye Bioscience (NASDAQ : SKYE), une société biotechnologique en phase clinique spécialisée dans les traitements de l'obésité et des troubles métaboliques, a programmé sa conférence téléphonique sur les résultats du premier trimestre 2025 pour le 8 mai 2025 à 13h30 PT/16h30 ET. La société publiera ses résultats financiers après la clôture du marché le même jour. Les investisseurs pourront accéder au webinaire en direct, au communiqué de résultats, aux tableaux financiers et à la présentation via le site des Relations Investisseurs de Skye. Une rediffusion et une transcription seront disponibles après l'appel sur la même plateforme.
Skye Bioscience (NASDAQ: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen von Adipositas und Stoffwechselerkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Ergebnissen des ersten Quartals 2025 für den 8. Mai 2025 um 13:30 Uhr PT/16:30 Uhr ET angesetzt. Das Unternehmen wird die Finanzergebnisse am selben Tag nach Börsenschluss veröffentlichen. Investoren können über die Investor-Relations-Website von Skye auf das Live-Webcast, die Ergebnisveröffentlichung, Finanztabellen und die Präsentation zugreifen. Eine Aufzeichnung und das Transkript werden nach der Telefonkonferenz auf derselben Plattform verfügbar sein.
- None.
- None.
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
When will Skye Bioscience (SKYE) release its Q1 2025 earnings?
What time is Skye Bioscience's Q1 2025 earnings call?
How can investors access Skye Bioscience's Q1 2025 earnings call?
What is Skye Bioscience's main business focus?
